US Stock Movement | Pneumococcal Vaccine Meets Late-Stage Clinical Trial Target, Vaxcyte (PCVX.US) Opens Over 50% Higher

智通财经2026/10/05 13:46

Show original

According to reports from Zhihu Finance APP, on Monday, Vaxcyte (PCVX.US) opened over 50% higher, with gains of around 53% at the time of publication, and a market capitalization of 12.8 billions USD. The surge comes after the company's pneumococcal vaccine met its late-stage clinical trial goals. According to company assessments, VAX-31—a 31-valent pneumococcal conjugate vaccine under investigation—achieved positive topline results in its pivotal Phase III OPUS-1 trial. The trial evaluated the candidate vaccine’s safety, tolerability, and immunogenicity in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 achieved all pre-specified co-primary immunogenicity endpoints in subjects aged 50 years and older. These trial results will serve as the foundation for the upcoming Biologics License Application to be submitted to the U.S. Food and Drug Administration.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Elon Musk said his company may find a better way to manufacture chips.

智通财经•2026/10/11 07:36

BP is safely restarting production at its Na Kika and Thunder Horse platforms in the Gulf of Mexico.

智通财经•2026/10/11 05:16

BP is safely restarting production at the Na Kika and Thunder Horse platforms.

智通财经•2026/10/11 04:46

The overseas asset returns of the Bank of Korea are expected to reach nearly 17 trillion won in 2025, a year-on-year increase of 32%.

智通财经•2026/10/11 04:06